Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy
Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy
Recruiting · NCT06902896 · Registry updated 2026-07-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety and Efficacy of FAP iCDC in End-stage Dilated Cardiomyopathy | Cardiomegaly, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, cardiomyopathy, cardiovascular disorder, dilated cardiomyopathy, heart disorder, heart failure, hereditary disease, laminopathy | Recruiting | Phase 1 / Phase 2 | 2026-07-14 | NCT06902896 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 561 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Second Affiliated Hospital, School of Medicine, Zhejiang University | Hangzhou | China | 18 |